Robert C Hsu
Overview
Explore the profile of Robert C Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
3
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benjamin D, Hsu R
Front Oncol
. 2025 Jan;
14:1457006.
PMID: 39882447
Penile cancer is a rare genitourinary malignancy which can be treated with surgery or radiation for localized disease, but often requires systemic treatment with chemotherapy for recurrent or metastatic disease....
2.
Poei D, Ali S, Thomas J, Nieva J, Hsu R
Cancer Res Commun
. 2025 Jan;
5(2):277-286.
PMID: 39807831
This study identified a higher incidence of ALK alterations in Hispanic patients with NSCLC (12.76%) compared with that in non-Hispanic patients (5.36%) treated at a large academic center in Los...
3.
Hsu R, Tsai K, Benjamin D, Chennapan K, Wojcik K, Lee A, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539437
Background: Previous studies on Hispanic thyroid cancer cases show sex disparities and an increased prevalence of large tumor sizes and nodal involvement. Here, we characterized Hispanic thyroid cancer cases in...
4.
Benjamin D, Padula W, Hsu R
Gynecol Oncol Rep
. 2024 Mar;
52:101351.
PMID: 38449799
Over the past five years (2019-2023), several new targeted therapies and immunotherapy has been approved in treating relapsed cervical, ovarian, and endometrial cancers. Concurrently, there has been growing recognition of...
5.
Cheng J, Hsu R, Nieva J, Thomas J
Oral Oncol
. 2023 Oct;
147:106597.
PMID: 37857230
Immunotherapies such as immune checkpoint inhibitors have shown promising results in solid tumors associated with BRCA2, but there are no consistent predictors for who will respond to immunotherapy. More research...
6.
Hsu R, Burak J, Tiwari S, Chakraborti C, Sander G
Ochsner J
. 2016 Sep;
16(3):304-8.
PMID: 27660581
Background: Chagas disease (CD), caused by Trypanosoma cruzi, affects 6-7 million people worldwide annually, primarily in Central and South America, and >300,000 people in the United States. CD consists of...